PharmaLytica 2021 Hyderabad review.

Dr Reddys hopes to finish Phase 3 trials of COVID-19 vaccine by March-May

October 29, 2020

Dr Reddys Laboratories on Wednesday said the Phase 3 trials of Russia's Sputnik V vaccine for COVID-19 in India to be conducted by it are expected to be completed by the end of March depending on approvals and data validation. The city-headquartered drug maker, which has received approval from the Drug Control General of India (DCGI) for conducting human clinical trials of Sputnik V, was expected to complete the Phase 2 trials by December, Dr Reddys Chief Executive Officer Erez Israeli said.

"Phase-3, we should finish somewhere by March and then of course it depends on the ability to compile the data, obtain the approvals etc. It can be as early as the end of March or April /May and beyond. It depends on the results. Its a combination of phase-2, global phase-3 and phase-3 in India," he told reporters here after announcing the company's Q2 results.

He said the company needed to engage 100 and 1,400 volunteers for Phase 2 and 3 trials respectively. Dr. Reddys and Russian Direct Investment Fund (RDIF), Russias sovereign wealth fund, entered into a partnership last month to conduct clinical trials of Sputnik V and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddys upon regulatory approval in India.


This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More